House Vs. Senate Drug Pricing Bills: A Snapshot Of Differences
Senate and House will likely have to reconcile differences on drug pricing legislation as Senate HELP Committee seeks public comment on a discussion draft.
You may also be interested in...
Measure clarifies the meaning of new chemical entity by replacing the term ‘active ingredient,’ which encompasses esters and salts, with ‘active moiety’ as defined by the FDA; legal experts are skeptical the measure will generate cost savings and say it gives the agency wide latitude to make future changes in eligibility for 5-year exclusivity.
Now that the Senate Finance Committee has unveiled its bill and House leadership has outlined its approach, less comprehensive drug pricing legislation is losing the limelight. But may of the the bills could still have a meaningful impact on pharma, and might even become law, if only because they would be an easier way for politicians to show they were doing something to address the issue.
Senate Drug Pricing Legislation Clears Committee With Generic Exclusivity “Parking” Provision Unchanged
US Senate health committee advanced the Lower Health Care Costs Act with few pharma-related changes. Bill’s drug pricing provisions include the CREATES Act and a requirement that manufacturers report to HHS on price increases.